Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:20609189rdf:typepubmed:Citationlld:pubmed
pubmed-article:20609189lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:20609189lifeskim:mentionsumls-concept:C0024501lld:lifeskim
pubmed-article:20609189lifeskim:mentionsumls-concept:C0019004lld:lifeskim
pubmed-article:20609189lifeskim:mentionsumls-concept:C0229671lld:lifeskim
pubmed-article:20609189lifeskim:mentionsumls-concept:C0007222lld:lifeskim
pubmed-article:20609189lifeskim:mentionsumls-concept:C0005516lld:lifeskim
pubmed-article:20609189lifeskim:mentionsumls-concept:C0052181lld:lifeskim
pubmed-article:20609189pubmed:issue3lld:pubmed
pubmed-article:20609189pubmed:dateCreated2010-7-8lld:pubmed
pubmed-article:20609189pubmed:abstractTextThe aim of this study was to investigate the relationship between serum apolipoprotein (apo) A-IV levels and markers for atherosclerosis, including carotid intima-media thickness (CIMT) and the ankle-brachial index (ABI), in hemodialysis patients. We performed a cross-sectional study involving 116 maintenance hemodialysis patients (70 males; median age, 64 years), measuring CIMT, ABI, the usual laboratory examinations, and serum apo A-IV before the dialysis session. The apo A-IV concentration was measured by a noncompetitive ELISA. Serum apo A-IV concentrations were significantly lower in hemodialysis patients with cardiovascular disease and plaque in the carotid artery. The apo A-IV level was positively associated with urea nitrogen and creatinine, and negatively associated with age, interleukin-6, the neutrophil/lymphocyte ratio, and maximum CIMT. Moreover, serum apo A-IV concentrations were significantly lower in the low ABI group. On logistic analysis, patients with high apo A-IV levels had a lower odds ratio for atherosclerosis (maximum CIMT > 1.0) and cardiovascular disease compared to patients with low apo A-IV levels. On stepwise multivariate regression analysis, the serum apo A-IV level was independently associated with creatinine, the neutrophil/lymphocyte ratio, and the maximum CIMT. Serum apo A-IV is associated with atherosclerotic lesions in hemodialysis patients. Apo A-IV levels may be useful for estimating the risk of cardiovascular disease in dialysis patients.lld:pubmed
pubmed-article:20609189pubmed:languageenglld:pubmed
pubmed-article:20609189pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20609189pubmed:citationSubsetIMlld:pubmed
pubmed-article:20609189pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20609189pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20609189pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20609189pubmed:statusMEDLINElld:pubmed
pubmed-article:20609189pubmed:monthJunlld:pubmed
pubmed-article:20609189pubmed:issn1744-9987lld:pubmed
pubmed-article:20609189pubmed:authorpubmed-author:HattoriHiroak...lld:pubmed
pubmed-article:20609189pubmed:authorpubmed-author:HondaHirokazu...lld:pubmed
pubmed-article:20609189pubmed:authorpubmed-author:AkizawaTadaoTlld:pubmed
pubmed-article:20609189pubmed:authorpubmed-author:WatanabeMakot...lld:pubmed
pubmed-article:20609189pubmed:authorpubmed-author:MatsumotoKeiKlld:pubmed
pubmed-article:20609189pubmed:authorpubmed-author:OmoriMahoMlld:pubmed
pubmed-article:20609189pubmed:issnTypeElectroniclld:pubmed
pubmed-article:20609189pubmed:volume14lld:pubmed
pubmed-article:20609189pubmed:ownerNLMlld:pubmed
pubmed-article:20609189pubmed:authorsCompleteYlld:pubmed
pubmed-article:20609189pubmed:pagination341-8lld:pubmed
pubmed-article:20609189pubmed:meshHeadingpubmed-meshheading:20609189...lld:pubmed
pubmed-article:20609189pubmed:meshHeadingpubmed-meshheading:20609189...lld:pubmed
pubmed-article:20609189pubmed:meshHeadingpubmed-meshheading:20609189...lld:pubmed
pubmed-article:20609189pubmed:meshHeadingpubmed-meshheading:20609189...lld:pubmed
pubmed-article:20609189pubmed:meshHeadingpubmed-meshheading:20609189...lld:pubmed
pubmed-article:20609189pubmed:meshHeadingpubmed-meshheading:20609189...lld:pubmed
pubmed-article:20609189pubmed:meshHeadingpubmed-meshheading:20609189...lld:pubmed
pubmed-article:20609189pubmed:meshHeadingpubmed-meshheading:20609189...lld:pubmed
pubmed-article:20609189pubmed:meshHeadingpubmed-meshheading:20609189...lld:pubmed
pubmed-article:20609189pubmed:meshHeadingpubmed-meshheading:20609189...lld:pubmed
pubmed-article:20609189pubmed:meshHeadingpubmed-meshheading:20609189...lld:pubmed
pubmed-article:20609189pubmed:meshHeadingpubmed-meshheading:20609189...lld:pubmed
pubmed-article:20609189pubmed:meshHeadingpubmed-meshheading:20609189...lld:pubmed
pubmed-article:20609189pubmed:meshHeadingpubmed-meshheading:20609189...lld:pubmed
pubmed-article:20609189pubmed:meshHeadingpubmed-meshheading:20609189...lld:pubmed
pubmed-article:20609189pubmed:meshHeadingpubmed-meshheading:20609189...lld:pubmed
pubmed-article:20609189pubmed:meshHeadingpubmed-meshheading:20609189...lld:pubmed
pubmed-article:20609189pubmed:meshHeadingpubmed-meshheading:20609189...lld:pubmed
pubmed-article:20609189pubmed:meshHeadingpubmed-meshheading:20609189...lld:pubmed
pubmed-article:20609189pubmed:year2010lld:pubmed
pubmed-article:20609189pubmed:articleTitleImpact of serum apolipoprotein A-IV as a marker of cardiovascular disease in maintenance hemodialysis patients.lld:pubmed
pubmed-article:20609189pubmed:affiliationDepartment of Nephrology, Gyoutoku Sougou Hospital, Chiba, Japan.lld:pubmed
pubmed-article:20609189pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:20609189pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
entrez-gene:337entrezgene:pubmedpubmed-article:20609189lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:20609189lld:entrezgene